Cullinan Therapeutics, Inc. (CGEM)
NASDAQ: CGEM · Real-Time Price · USD
13.84
-0.14 (-1.00%)
At close: May 22, 2026, 4:00 PM EDT
14.00
+0.16 (1.16%)
After-hours: May 22, 2026, 4:15 PM EDT
Cullinan Therapeutics Revenue
Revenue (ttm)
n/a
Revenue Growth
n/a
P/S Ratio
n/a
Revenue / Employee
n/a
Employees
109
Market Cap
850.58M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | - | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | 18.94M | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Arbutus Biopharma | 191.45M |
| Theravance Biopharma | 109.78M |
| Xencor | 97.36M |
| MeiraGTx Holdings | 79.76M |
| Omeros | 9.89M |
| Odyssey Therapeutics | 2.98M |
CGEM News
- 5 days ago - Cullinan post-EULAR share pullback ‘unwarranted,’ says Clear Street - TheFly
- 5 days ago - Cullinan Therapeutics receives orphan drug designation for CLN-049 - TheFly
- 5 days ago - Cullinan Therapeutics Receives FDA Orphan Drug Designation for CLN-049, a Novel FLT3xCD3 T Cell Engager, in Relapsed/Refractory Acute Myeloid Leukemia - GlobeNewsWire
- 6 days ago - Cullinan Therapeutics to Present Initial Clinical Data for CLN-978 in Treatment-Refractory Rheumatoid Arthritis and Systemic Lupus Erythematosus at EULAR 2026 Congress - GlobeNewsWire
- 16 days ago - Cullinan Therapeutics price target raised to $37 from $36 at Wedbush - TheFly
- 17 days ago - Cullinan Therapeutics reports Q1 EPS (75c), consensus (85c) - TheFly
- 17 days ago - Cullinan Therapeutics Provides Corporate Update and Reports First Quarter 2026 Financial Results - GlobeNewsWire
- 17 days ago - Cullinan Therapeutics Quarterly report: Q1 2026 - Filings